Physician profile
Anu Paul
NPI 1346575768
$4,439.32
in general payments reported to CMS, 2019-2025
35 companies · $418 in 2025
The $418 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $859 · 2021: $835 · 2022: $524 · 2023: $751 · 2024: $349 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,219.74 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $781.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $508.30 | 2019-2025 | Tagrisso, Airsupra, Imfinzi |
| Incyte Corporation | $358.53 | 2019-2023 | Jakafi |
| Pfizer INC. | $315.26 | 2019-2024 | |
| Janssen Biotech, INC. | $252.35 | 2019-2025 | Erleada, Akeega, Balversa |
| Seagen INC. | $239.26 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $236.36 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $233.60 | 2020-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $195.39 | 2021-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $190.27 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $139.97 | 2020-2022 | |
| Genzyme Corporation | $114.49 | 2019-2025 | |
| Gilead Sciences, INC. | $88.15 | 2024-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $87.89 | 2021-2025 | Libtayo |
| Tempus Ai, INC | $87.53 | 2024-2025 | Xt Cdx |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $70.35 | 2021-2025 | Reblozyl |
| Eisai INC. | $59.37 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.35 | 2019-2020 | |
| Puma Biotechnology, INC. | $40.04 | 2019-2020 | |
| Astellas Pharma US INC | $38.82 | 2022-2025 | Xtandi |
| Alexion Pharmaceuticals, INC. | $36.84 | 2019 | |
| Karyopharm Therapeutics INC. | $33.65 | 2020 | |
| Taiho Oncology, INC. | $30.56 | 2021 | |
| Amgen INC. | $30.09 | 2019-2020 | |
| Beigene USA, INC. | $28.15 | 2022-2023 | Brukinsa |
| Secura Bio, INC. | $27.75 | 2019 | |
| Exelixis INC. | $27.47 | 2023 | Cabometyx |
| Emd Serono, INC. | $27.16 | 2019 | |
| Coherus Oncology, INC. | $20.03 | 2021 | |
| Verastem, INC. | $18.84 | 2019 | |
| Daiichi Sankyo INC. | $18.74 | 2020 | |
| Pharmacosmos Therapeutics INC. | $17.07 | 2024 | Cosela |
| Aveo Pharmaceuticals, INC. | $16.02 | 2023 | Fotivda |
| Abbvie INC. | $13.72 | 2021 | |
| Genentech USA, INC. | $13.54 | 2023 | Polivy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.